In Vitro Anti-Osteoporosis Properties of Diverse Korean Drynariae rhizoma Phenolic Extracts

Kang, Suk-Nam; Lee, Jong Seok; Park, Joung-Hyun; Cho, Jae‐Hyeon; Park, Jaehong; Cho, Kwang-Keun; Lee, Ok‐Hwan; Kim, Il-Suk

doi:10.3390/nu6041737

Cited by 23 publications

(12 citation statements)

References 45 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EDHB is a polyphenol found in many plants, e.g., peanut seed testa. EDHB has been the subject of interest of the scientists for its various properties, including antibacterial and antioxidant [20], cardioprotective [21], myoprotective [22] anti-osteoporosis activity [23], chelating iron bounding enzymes [24] and modifying hypoxia tolerance [25]. Moreover, there are reports indicating that collagen production can be reduced by EDHB, due to its abilities to inhibit prolyl hydroxylase [26,27].…”

Section: Introductionmentioning

confidence: 99%

Antibacterial Activity of Protocatechuic Acid Ethyl Ester on Staphylococcus aureus Clinical Strains Alone and in Combination with Antistaphylococcal Drugs

et al. 2015

View full text Add to dashboard Cite

Abstract:The aim of the presented study was to examine in vitro the antibacterial activity of protocatechuic acid ethyl ester (ethyl 3,4-dihydroxybenzoate, EDHB) against Staphylococcus aureus clinical isolates alone and in the combination with four selected antibiotics. The EDHB antimicrobial activity was tested against twenty S. aureus strains isolated from the clinical samples, and three reference strains. The phenotypes and genotypes of resistance to methicillin for the tested strains were defined as well as the phenotypic resistance to macrolides, lincosamides and streptogramin B (MLSB). EDHB displayed diverse activity against examined S. aureus strains with the minimal inhibitory concentration (MIC) within the range from 64 to 1024 µg/mL. Addition of ¼ MIC of EDHB into the Mueller-Hinton Agar (MHA) resulted in augmented antibacterial effect in the presence of clindamycin. In the case of cefoxitin no synergistic effect with EDHB was noted. For erythromycin and vancomycin the decrease of mean MICs in the presence of EDHB was observed but did not reach statistical significance. The results of the present study showed that in vitro EDHB possesses antibacterial activity against S. aureus clinical strains and OPEN ACCESSMolecules 2015, 20 13537 triggers a synergistic antimicrobial effect with clindamycin and to the lesser extent with erythromycin and vancomycin.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibacterial Activity of Protocatechuic Acid Ethyl Ester on Staphylococcus aureus Clinical Strains Alone and in Combination with Antistaphylococcal Drugs

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Gu-Sui-Bu (GSB) has been used for the treatment of fractures, osteoporosis, rheumatoid arthritis, and head injuries (Shih et al, 2012; Wang et al, 2012; Saravanan et al, 2013; Liao et al, 2015). Studies have reported that extracts of Gu-Sui-Bu exhibit immune-promoting, anti-inflammatory, antiosteoporotic, and neuroprotective activities (Anuja et al, 2010; Chen et al, 2011b; Wang et al, 2012; Saravanan et al, 2013; Kang et al, 2014; Wang et al, 2016b). The natural compounds of Gu-Sui-Bu include naringin and flavonoids (Wang et al, 2008; Chen et al, 2011b).…”

Section: Resultsmentioning

confidence: 99%

Effects of Chinese Herbal Medicines on the Risk of Overall Mortality, Readmission, and Reoperation in Hip Fracture Patients

et al. 2019

View full text Add to dashboard Cite

Hip fracture is a major public health concern, with high incidence rates in the elderly worldwide. Hip fractures are associated with increased medical costs, patient dependency on families, and higher rates of morbidity and mortality. Chinese herbal medicine (CHM) is typically characterized as cost-effective and suitable for long-term use with few side effects. To better understand the effects of CHM on hip fracture patients, we utilized a population-based database to investigate the demographic characteristics, cumulative incidence of overall mortality, readmission, reoperation, and patterns of CHM prescription. We found that CHM usage was associated with a lower risk of overall mortality [ P = 0.0009; adjusted hazard ratio (HR): 0.47, 95% confidence interval (CI): 0.30–0.73], readmission ( P = 0.0345; adjusted HR: 0.67, 95% CI: 0.46–0.97), and reoperation ( P = 0.0009; adjusted HR: 0.57, 95% CI: 0.40–0.79) after adjustment for age, type of hip fracture, surgical treatment type, and comorbidities. We also identified the herbal formulas, single herbs, and prescription patterns for the treatment of hip fracture by using association rule mining and network analysis. For hip fracture patients, the most common CHM coprescription pattern was Du-Zhong (DZ) → Xu-Duan (XD), followed by Du-Huo-Ji-Sheng-Tang (DHJST) → Shu-Jing-Huo-Xue-Tang (SJHXT), and Gu-Sui-Bu (GSB) → Xu-Duan (XD). Furthermore, XD was the core prescription, and DZ, GSB, SJHXT, and DHJST were important prescriptions located in cluster 1 of the prescription patterns. This study provides evidence for clinical CHM use as an adjunctive therapy that offers benefits to hip fracture patients.

show abstract

“…More and more Chinese herbs have been historically used to treat bone metabolic diseases and known for anti-osteoporotic drugs [ 48 – 51 ]. The anti-osteoporosis effect of Rhizoma Drynariae and its extracts have attracted world-wide attention [ 52 , 53 ]. Our systematic review is to assess the efficacy and safety of Qianggu Capsule ( Rhizoma Drynariae ) in osteoporosis therapy.…”

Section: Discussionmentioning

confidence: 99%

Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine

Wei

Ai-li

Shen

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundQianggu Capsule, a Chinese patent medicine, has been widely applied in the clinical practice of primary osteoporosis (POP) in recent years. This study aims to summarize the effectiveness and safety of Qianggu Capsule in treating POP.MethodsWe searched seven electronic databases, all searches ended in 30 September, 2015. All randomised controlled trials comparing the efficacy of Qianggu Capsule treatment with no treatment, placebo or conventional therapy for POP were included. Combined therapies of Qianggu Capsule were also included. Cochrane risk of bias tool was used to assess methodological quality of primary studies. Revman 5.2.0 software was used for data analysis.ResultsTen trials were enrolled. The combined effect showed that Qianggu Capsule plus Caltrate D was better than Caltrate D on lumbar spine bone mineral density (BMD) (MD = 0.05 g/cm2; 95% CI: 0.02–0.07; P = 0.0004), femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.001), femoral great trochanter BMD (MD = 0.04 g/cm2; 95% CI: 0.03–0.06; P < 0.001). Meta-analysis exhibited a significant antiosteoporosis effect of Qianggu Capsule on femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.003) and femoral trochanteric BMD (MD = 0.07 g/cm2; 95% CI: 0.02–0.12; P = 0.006) compared with α-D3 capsule. However, the methodological quality of included studies was low. Constipation and dry mouth were the most common adverse drug reactions of Qianggu Capsule. Finally the evidence level was evaluated to be low or very low.ConclusionsThe effect of Qianggu Capsule for POP was supported in improving BMD. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research.

show abstract

In Vitro Anti-Osteoporosis Properties of Diverse Korean Drynariae rhizoma Phenolic Extracts

Cited by 23 publications

References 45 publications

Antibacterial Activity of Protocatechuic Acid Ethyl Ester on Staphylococcus aureus Clinical Strains Alone and in Combination with Antistaphylococcal Drugs

Antibacterial Activity of Protocatechuic Acid Ethyl Ester on Staphylococcus aureus Clinical Strains Alone and in Combination with Antistaphylococcal Drugs

Effects of Chinese Herbal Medicines on the Risk of Overall Mortality, Readmission, and Reoperation in Hip Fracture Patients

Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine

Contact Info

Product

Resources

About